Clazakizumab is a high-affinity monoclonal antibody targeting interleukin-6 (IL-6). It is being investigated for applications in COVID-19 cytokine storm, psoriatic arthritis, and renal transplant rejection, with supporting evidence from both in vitro and in vivo research studies.